OP0243 Predictors of remission at week 12 in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab treatment in the ability-3 study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.6467
Abstract: Background Patients (pts) with non-radiographic axial spondyloarthritis (nr-axSpA) who fail nonsteroidal anti-inflammatory drug (NSAID) therapy are candidates for tumor necrosis factor inhibitor (TNFi) therapy if they have objective signs of inflammation. Baseline predictors of response… read more here.
Keywords: abbvie; pfizer; open label; ability ... See more keywords